The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population

Loganathan, Aravinthan; McMorrow, Fionnuala; Lu, Hui; Li, Danyang; Mulhearn, Ben; McHugh, Neil; Tansley, Sarah

doi:10.3389/fimmu.2022.975939

Cited by 8 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 40 , 41 In contrast, commercial enzyme-linked immunosorbent assays (ELISA) have demonstrated agreement with immunoprecipitation in detecting several MSAs. 42 , 43 …”

Section: Diagnosismentioning

confidence: 99%

Dermatomyositis: Practical Guidance and Unmet Needs

Cassard,

Seraly,

Riegert

et al. 2024

ITT

View full text Add to dashboard Cite

Dermatomyositis is a heterogeneous idiopathic inflammatory myopathy associated with various cutaneous manifestations and variable presence of myositis, interstitial lung disease, and other visceral organ involvement. An accurate diagnosis of dermatomyositis requires correlating clinical examination findings with serological and histological findings. Familiarity with pathognomonic and common cutaneous manifestations of dermatomyositis, which are highlighted here, can be especially helpful in making an accurate diagnosis. Additionally, evaluating patients for presence of myositis-specific autoantibodies can further support or refute a dermatomyositis diagnosis. When present, myositis-specific autoantibodies can also help guide workups for various dermatomyositis-associated manifestations, as each is associated with relatively distinct clinical characteristics. Evaluating patients for various systemic manifestations often relies on expert opinion recommendations; however, societal guideline statements concerning the evaluation of some manifestations have recently been described. Although malignancy-associated dermatomyositis is a well-accepted subtype, there is limited evidence to support extensive malignancy screening has a favorable benefit–risk ratio in most dermatomyositis patients. However, recent research has uncovered novel associations between dermatomyositis and malignancy, suggesting the possibility of identifying high-risk subsets of dermatomyositis patients in whom malignancy screening may have a high value. Treatment for dermatomyositis has remained largely unchanged over the past several decades. Although many dermatomyositis patients can be effectively treated with current options, either as monotherapy or with combination regimens, there is a need for more targeted and effective DM therapies, in general, and for MDA5(+) dermatomyositis-associated rapidly progressive interstitial lung disease. Fortunately, significant current and emerging research activities evaluating various novel medications for dermatomyositis provide hope for exciting future advances in patients with this intriguing immune-mediated disease.

show abstract

“… 40 , 41 In contrast, commercial enzyme-linked immunosorbent assays (ELISA) have demonstrated agreement with immunoprecipitation in detecting several MSAs. 42 , 43 …”

Section: Diagnosismentioning

confidence: 99%

Dermatomyositis: Practical Guidance and Unmet Needs

Cassard,

Seraly,

Riegert

et al. 2024

ITT

View full text Add to dashboard Cite

show abstract

“…In addition, although IP-MS method holds promise for the discovery of novel biomarkers, due to the current lack of standardization and harmonization, it will likely remain a valuable research tool, but a challenge for it to meet In Vitro Diagnostic Regulations (IVDR) requirements [ 43 ]. It should be noted that ELISA has been routinely used in many countries for decades and some ELISA AIM-S autoantibody kits have been validated by IP with very good agreement [ 44 ▪ ]. In addition, newer platforms such as the use of LIA is limited and PMAT (discussed below) are not currently available in some countries.…”

Section: Immunoprecipitation and Immunoprecipitation-mass Spectroscopymentioning

confidence: 99%

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Choi,

Satoh,

Fritzler

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This manuscript reviews recently published advances in the identification of autoimmune inflammatory myopathies (AIM)-specific and AIM-related autoantibodies considered of value in the workup of patients suspected of having AIM. Newer autoantibodies, developments, and advances in the methodology of testing, the gaps and pitfalls in using these assays as diagnostic biomarkers, and the importance of considering overlap diseases and unique clinical AIM phenotypes are discussed. Recent findings Summary The spectrum of autoantibodies and related biomarkers in AIM continues to expand. Many of these have clear clinical implications in regard to subsets and overlap conditions of AIM, associated malignancy and pathological findings.

show abstract

Autoantibody evaluation in idiopathic inflammatory myopathies

Tebo

2024

Advances in Clinical Chemistry

View full text Add to dashboard Cite

The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population

Cited by 8 publications

References 21 publications

Dermatomyositis: Practical Guidance and Unmet Needs

Dermatomyositis: Practical Guidance and Unmet Needs

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Autoantibody evaluation in idiopathic inflammatory myopathies

Contact Info

Product

Resources

About